Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
Blood (2014)
  • John C. Byrd, Ohio State University
  • John M. Pagel, University of Washington
  • Farrukh T. Awan, Ohio State University
  • Andres Forero, University of Alabama at Birmingham
  • Ian W. Flinn, Sarah Cannon Research Institute
  • Delva P. Deauna-Limayo, Nevada Cancer Institute
  • Stephen E. Spurgeon, Oregon Health & Science University
  • Leslie A. Andritsos, Ohio State University
  • Ajay K. Gopal, University of Washington
  • John P. Leonard, Cornell University
  • Amy J. Eisenfeld
  • Jeannette E. Bannink
  • Scott C. Stromatt
  • Richard R. Furman, Cornell University
Link
Disciplines
Publication Date
February 27, 2014
DOI
10.1182/blood-2013-07-512137
Citation Information
John C. Byrd, John M. Pagel, Farrukh T. Awan, Andres Forero, et al.. "A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia" Blood Vol. 123 Iss. 9 (2014) p. 1302 - 1308
Available at: http://works.bepress.com/john-pagel/100/